A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3x4 Factorial Design Trial to Evaluate Telmisartan 20 and 80 mg Tablets in Combination With Ramipril 1.25, 10, and 20 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study
- NCT00281593
- PHASE3
- INTERVENTIONAL
Last updated: 2017-12-28
Purpose of Trial
To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension.
This study is for people with
Hypertension
Interventions being studied
Telmisartan
Ramipril
Inclusion Criteria:
* Male and female patients \>=18 years of age with Stage I or II hypertension defined as:
* a mean seated cuff diastolic blood pressure \>=95 and \<=119 mmHg Main
Exclusion Criteria:
* Pregnant
* breast-feeding
* unwilling to use birth control during the study
* secondary hypertension
* SBP\>=180 mmHg
* DBP\>=120 mmHg
* severe renal dysfunction
* hepatic insufficiency
* stroke within the last 6 months
* myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months
* unstable or uncontrolled diabetes
* history of angioedema of either of the study drugs, and hypersensitivity to the study drugs.
ELIGIBILITY
Gender: ALL
Age: 18+
Healthy Volunteers: No
70 Locations
Glendale
1236.1.511 Boehringer Ingelheim Investigational Site
Arizona, United States
Tempe
1236.1.574 Boehringer Ingelheim Investigational Site
Arizona, United States
Tucson
1236.1.501 Boehringer Ingelheim Investigational Site
Arizona, United States
Tucson
1236.1.557 Boehringer Ingelheim Investigational Site
Arizona, United States
Buena Park
1236.1.523 Boehringer Ingelheim Investigational Site
California, United States
Concord
1236.1.514 Boehringer Ingelheim Investigational Site
California, United States
Encinitas
1236.1.560 Boehringer Ingelheim Investigational Site
California, United States
Long Beach
1236.1.573 Boehringer Ingelheim Investigational Site
California, United States
Los Angeles
1236.1.516 Boehringer Ingelheim Investigational Site
California, United States
Roseville
1236.1.529 Boehringer Ingelheim Investigational Site
California, United States
Tustin
1236.1.519 Boehringer Ingelheim Investigational Site
California, United States
Westlake Village
1236.1.543 Boehringer Ingelheim Investigational Site
California, United States
Boulder
1236.1.528 Boehringer Ingelheim Investigational Site
Colorado, United States
Farmington
1236.1.530 Boehringer Ingelheim Investigational Site
Connecticut, United States
DeLand
1236.1.572 Boehringer Ingelheim Investigational Site
Florida, United States
Hialeah
1236.1.577 Boehringer Ingelheim Investigational Site
Florida, United States
Jupiter
1236.1.526 Boehringer Ingelheim Investigational Site
Florida, United States
Largo
1236.1.527 Boehringer Ingelheim Investigational Site
Florida, United States
Naples
1236.1.503 Anchor Research Center
Florida, United States
New Port Richey
1236.1.520 Boehringer Ingelheim Investigational Site
Florida, United States
Pembroke Pines
1236.1.571 Boehringer Ingelheim Investigational Site
Florida, United States
Blue Ridge
1236.1.565 Boehringer Ingelheim Investigational Site
Georgia, United States
Meridian
1236.1.538 Boehringer Ingelheim Investigational Site
Idaho, United States
Peoria
1236.1.532 Boehringer Ingelheim Investigational Site
Illinois, United States
Avon
1236.1.553 Boehringer Ingelheim Investigational Site
Indiana, United States
Jeffersonville
1236.1.546 River Cities Cardiology Research Inst of Middle America
Indiana, United States
Valparaiso
1236.1.563 Boehringer Ingelheim Investigational Site
Indiana, United States
Newton
1236.1.517 Boehringer Ingelheim Investigational Site
Kansas, United States
Wichita
1236.1.531 Boehringer Ingelheim Investigational Site
Kansas, United States
Richmond
1236.1.566 Boehringer Ingelheim Investigational Site
Kentucky, United States
Auburn
1236.1.551 Boehringer Ingelheim Investigational Site
Maine, United States
Haverhill
1236.1.536 Boehringer Ingelheim Investigational Site
Massachusetts, United States
North Dartmouth
1236.1.576 Boehringer Ingelheim Investigational Site
Massachusetts, United States
West Yarmouth
1236.1.561 Clinical Research Center of Cape Cod
Massachusetts, United States
Cadillac
1236.1.555 Boehringer Ingelheim Investigational Site
Michigan, United States
Troy
1236.1.509 Boehringer Ingelheim Investigational Site
Michigan, United States
Excelsior Springs
1236.1.541 Boehringer Ingelheim Investigational Site
Missouri, United States
Las Vegas
1236.1.556 Boehringer Ingelheim Investigational Site
Nevada, United States
Toms River
1236.1.525 Physicians Research Center, LLC, Toms River
New Jersey, United States
Albuquerque
1236.1.508 Boehringer Ingelheim Investigational Site
New Mexico, United States
Albuquerque
1236.1.522 Boehringer Ingelheim Investigational Site
New Mexico, United States
Albuquerque
1236.1.542 Boehringer Ingelheim Investigational Site
New Mexico, United States
Cincinnati
1236.1.547 Boehringer Ingelheim Investigational Site
Ohio, United States
Columbus
1236.1.567 Boehringer Ingelheim Investigational Site
Ohio, United States
Kettering
1236.1.515 Boehringer Ingelheim Investigational Site
Ohio, United States
Tulsa
1236.1.575 Boehringer Ingelheim Investigational Site
Oklahoma, United States
Corvallis
1236.1.554 Boehringer Ingelheim Investigational Site
Oregon, United States
Eugene
1236.1.524 Boehringer Ingelheim Investigational Site
Oregon, United States
Medford
1236.1.544 Boehringer Ingelheim Investigational Site
Oregon, United States
Portland
1236.1.545 Boehringer Ingelheim Investigational Site
Oregon, United States
Erie
1236.1.569 Boehringer Ingelheim Investigational Site
Pennsylvania, United States
Harleysville
1236.1.505 Ledeeach Family Medicine
Pennsylvania, United States
Tipton
1236.1.564 Boehringer Ingelheim Investigational Site
Pennsylvania, United States
Cumberland
1236.1.534 Boehringer Ingelheim Investigational Site
Rhode Island, United States
Spartanburg
1236.1.539 Boehringer Ingelheim Investigational Site
South Carolina, United States
Carrollton
1236.1.568 Boehringer Ingelheim Investigational Site
Texas, United States
Houston
1236.1.549 Boehringer Ingelheim Investigational Site
Texas, United States
Houston
1236.1.559 Boehringer Ingelheim Investigational Site
Texas, United States
San Antonio
1236.1.548 Boehringer Ingelheim Investigational Site
Texas, United States
San Antonio
1236.1.550 Boehringer Ingelheim Investigational Site
Texas, United States
The Colony
1236.1.570 Boehringer Ingelheim Investigational Site
Texas, United States
Salt Lake City
1236.1.510 Boehringer Ingelheim Investigational Site
Utah, United States
Salt Lake City
1236.1.513 Boehringer Ingelheim Investigational Site
Utah, United States
Salt Lake City
1236.1.521 Boehringer Ingelheim Investigational Site
Utah, United States
Sandy
1236.1.512 Boehringer Ingelheim Investigational Site
Utah, United States
Sandy
1236.1.535 Boehringer Ingelheim Investigational Site
Utah, United States
Falls Church
1236.1.502 Boehringer Ingelheim Investigational Site
Virginia, United States
Madison
1236.1.504 Boehringer Ingelheim Investigational Site
Wisconsin, United States
Madison
1236.1.540 Boehringer Ingelheim Investigational Site
Wisconsin, United States
Menomonee Falls
1236.1.562 Boehringer Ingelheim Investigational Site
Wisconsin, United States
Primary Contact(s)
Boehringer Ingelheim
Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at
ClinicalTrials.gov